Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 420 in Relapsed/Refractory Multiple Myeloma
NCT03836053Phase 1Terminated
- Sponsor
- Amgen
- Start
- Mar 2019
- Primary completion
- Apr 2022
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of pacanalotamab in multiple myeloma (MM) (2 arms), sponsored by Amgen. Primary endpoints: Number of Participants With Dose-limiting Toxicities, Number of Participants Who Experienced a Treatment-emergent Adverse Event up to 3 years and 1 more. Started Mar 2019; status: terminated.
02
Drugs
pacanalotamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03836053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03836053.